Mental health and suicidal thoughts in adults with glioblastoma in Germany
Mental Health and Suicidality in Glioblastoma Patients in Germany - a Multicenter Observational Study (SHINE-GLIO Study)
This project uses questionnaires and medical records to see if depression, anxiety, or other factors are linked to suicidal thoughts or behavior in adults with IDH wild-type glioblastoma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 176 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Essen Academic / other |
| Locations | 6 sites (Berlin and 5 other locations) |
| Trial ID | NCT07409584 on ClinicalTrials.gov |
What this trial studies
This observational study enrolls adults with IDH wild-type glioblastoma and collects standardized questionnaire data alongside a medical history, physical exam, and chart review. Participants complete validated instruments including the PHQ-8, GAD-7, a suicidality scale, EORTC-QLQ-C30, EORTC-QLQ-BN20, and a social support questionnaire. Clinical and imaging data from the medical record are combined with questionnaire responses to look for predictors or influencing factors for suicidal behavior. If unmet psycho-oncological needs are identified, participants are referred to appropriate services.
Who should consider this trial
Good fit: Adults aged 18 or older with a diagnosis of IDH wild-type glioblastoma who can give informed consent and complete questionnaires are appropriate candidates.
Not a fit: Patients with clinically significant aphasia or language barriers, a history of other malignant tumors, or known tumor-predisposition syndromes are excluded and may not be represented or benefit from the study's results.
Why it matters
Potential benefit: If successful, the findings could help clinicians recognize patients at higher risk for suicidal behavior and connect them to psycho-oncological support earlier.
How similar studies have performed: Related observational studies in broader cancer populations have linked depression and anxiety to suicidal behavior, but systematic, GBM-specific data remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of glioblastoma, IDH wild-type (CNS WHO classification of 2021) * Age ≥ 18 years Exclusion Criteria: * Participants with clinically significant aphasia or language barrier as assessed by the investigator * History of other malignant tumors * Known tumor predisposition syndrome (e.g., Li-Fraumeni syndrome, Cowden syndrome, etc.)
Where this trial is running
Berlin and 5 other locations
- Charite — Berlin, Germany (Recruiting)
- University Hospital Knappschaftskrankenhaus Bochum — Bochum, Germany (Not_yet_recruiting)
- University Hospital Essen — Essen, Germany (Recruiting)
- University hospital Hamburg Eppendorf — Hamburg, Germany (Recruiting)
- University hospital Heidelberg — Heidelberg, Germany (Recruiting)
- University hospital Muenster — Münster, Germany (Recruiting)
Study contacts
- Principal investigator: Sied Kebir, PD Dr. med. — University Hospital, Essen
- Study coordinator: Christoph Oster, Dr. med.
- Email: christoph.oster@uk-essen.de
- Phone: +49201-723-82598
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.